We are live on ! Find out more
LAB icon

Standard BioTools

135 hedge funds and large institutions have $864M invested in Standard BioTools in 2019 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 54 increasing their positions, 43 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 23

26% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 43

8.48% more ownership

Funds ownership: 93.19%101.67% (+8.5%)

3% more funds holding

Funds holding: 131135 (+4)

1% more capital invested

Capital invested by funds: $854M → $864M (+$10.1M)

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

97% less call options, than puts

Call options by funds: $6K | Put options by funds: $196K

Holders
135
Holders Change
+4
Holders Change %
+3.05%
% of All Funds
2.93%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
29
Increased
54
Reduced
43
Closed
23
Calls
$6K
Puts
$196K
Net Calls
-$190K
Net Calls Change
-$452K
Name Holding Trade Value Shares
Change
Change in
Stake
EIP
1
Easterly Investment Partners
Massachusetts
$97.3M -$18.2M -1,431,907 -15%
Primecap Management
2
Primecap Management
California
$81.1M -$26.7K -2,100 -0%
Russell Investments Group
3
Russell Investments Group
United Kingdom
$67M -$1.9M -149,060 -3%
Neuberger Berman Group
4
Neuberger Berman Group
New York
$62.9M -$1.42M -111,431 -2%
BlackRock
5
BlackRock
New York
$60.9M +$29.2M +2,293,024 +87%
Vanguard Group
6
Vanguard Group
Pennsylvania
$46.2M +$21.8M +1,711,187 +84%
Renaissance Technologies
7
Renaissance Technologies
New York
$31.1M +$4.68M +367,718 +17%
DCM
8
Driehaus Capital Management
Illinois
$26.4M -$4.89M -383,989 -15%
RI
9
RTW Investments
New York
$25.6M +$1.87M +146,537 +8%
Fidelity Investments
10
Fidelity Investments
Massachusetts
$22.4M
Morgan Stanley
11
Morgan Stanley
New York
$18.6M +$19M +1,490,345 +7,825%
PHS
12
PFM Health Sciences
California
$17M -$829K -65,106 -5%
State Street
13
State Street
Massachusetts
$16M +$9.18M +720,586 +125%
N
14
Nuveen
North Carolina
$13.9M +$14.3M +1,126,241 New
Acadian Asset Management
15
Acadian Asset Management
Massachusetts
$13M +$2.66M +208,982 +25%
Allianz Asset Management
16
Allianz Asset Management
Germany
$12.7M +$7.8M +612,774 +147%
Millennium Management
17
Millennium Management
New York
$12M -$3.27M -256,947 -21%
Citadel Advisors
18
Citadel Advisors
Florida
$11.9M +$677K +53,125 +6%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$9.95M +$2.15M +168,692 +26%
Two Sigma Advisers
20
Two Sigma Advisers
New York
$9.44M -$111K -8,700 -1%
GIM
21
Granahan Investment Management
Massachusetts
$9.06M -$582K -45,730 -6%
Norges Bank
22
Norges Bank
Norway
$7.97M +$3.93M +308,281 +91%
Two Sigma Investments
23
Two Sigma Investments
New York
$7.81M -$3.02M -236,795 -27%
PAM
24
Panagora Asset Management
Massachusetts
$7.79M +$2.25M +176,286 +39%
Invesco
25
Invesco
Georgia
$7.54M +$3.42M +268,362 +78%

LAB Hedge Fund Activity: Q2 2019 in Review

135 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q2 2019, worth a combined $864M — up 1.2% from $854M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new LAB positions and 23 closed out — a net gain of 6 holders — while 54 added to existing stakes and 43 trimmed.

The largest buyer was BlackRock, adding an estimated $29.2M. The largest seller was Easterly Investment Partners, cutting an estimated $18.2M.

  • 135 institutional investors held Standard BioTools (LAB) as of Q2 2019, up from 131 in Q1 2019.
  • Funds reported $864M of Standard BioTools stock for Q2 2019, up 1.2% quarter-over-quarter.
  • 29 funds opened new Standard BioTools positions in Q2 2019 and 23 closed out, a net change of +6 holders.
  • The largest Standard BioTools buyer in Q2 2019 was BlackRock, an estimated $29.2M added.
  • The largest Standard BioTools seller in Q2 2019 was Easterly Investment Partners, an estimated $18.2M sold.

Based on aggregated 13F filings for Q2 2019.